HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
26 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
S1PR1
sphingosine-1-phosphate receptor 1
Chromosome 1 · 1p21.2
NCBI Gene: 1901Ensembl: ENSG00000170989.11HGNC: HGNC:3165UniProt: P21453
235PubMed Papers
20Diseases
14Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedReceptor
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
T cell migrationG protein-coupled receptor bindingplasma membranesphingosine-1-phosphate receptor activitymultiple sclerosisrelapsing-remitting multiple sclerosisulcerative colitischronic progressive multiple sclerosis
✦AI Summary

S1PR1 (sphingosine-1-phosphate receptor 1) is a G-protein-coupled receptor that binds the bioactive lipid sphingosine-1-phosphate (S1P) and activates downstream signaling through Gi proteins, RAC1, SRC, and MAP kinases 1. The receptor plays critical roles in lymphocyte trafficking by maintaining an S1P gradient that guides immune cell egress from lymphoid tissues into circulation 23, and is essential for normal T-cell development and peripheral distribution. S1PR1 also regulates vascular biology, promoting endothelial integrity and controlling angiogenesis through the KLF2-S1PR1 pathway 4, while supporting cardiac morphogenesis and heart development 1. In lung adenocarcinoma, S1PR1 suppresses tumor progression by inhibiting COL5A1, MMP1, and SERPINE1 expression through a p-STAT1/miR-30c-5p/FOXA1 signaling axis, with reduced S1PR1 levels correlating with poor prognosis 5. S1PR1 emerges as a biomarker in endometriosis pathogenesis 6, and represents a therapeutic target in immune-mediated diseases; S1PR1-biased agonists maintain endothelial barrier function without excessive immunosuppression, offering advantages over pan-S1P modulators for treating inflammatory bowel disease and other endothelial dysfunction-associated conditions 73.

Sources cited
1
S1P signaling through S1PR1 affects cardiovascular function, regulates vascular tone, endothelial function and integrity, controls acute cardiac responses and chronic processes like hypertrophy
PMID: 32278039
2
S1PR1 maintains S1P gradient regulating lymphocyte trafficking; S1PR1 modulators cause receptor internalization preventing lymphocyte access to inflammation sites
PMID: 33983615
3
S1PR1 is downregulated in lung adenocarcinoma and suppresses tumor progression by inhibiting COL5A1, MMP1, SERPINE1 through p-STAT1/miR-30c-5p/FOXA1 pathway
PMID: 39551792
4
S1PR1 identified as biomarker in endometriosis alongside other immune cell-related genes involved in disease pathogenesis
PMID: 36524127
5
S1PR1 signaling promotes ischemia-induced angiogenesis when downstream KLF2-S1PR1 pathway is upregulated; ATF3 suppresses KLF2 and S1PR1 expression
PMID: 41195527
6
S1PR1 is highly expressed in endothelial cells; Gi-biased S1PR1 agonists protect endothelial barrier integrity without affecting immune cell egress in IBD
PMID: 39979282
7
S1PR1 participates in lymphocyte egress from secondary lymphoid tissue and prevention of gut homing in inflammatory bowel disease
PMID: 39322927
Disease Associationsⓘ20
multiple sclerosisOpen Targets
0.60Moderate
relapsing-remitting multiple sclerosisOpen Targets
0.60Moderate
ulcerative colitisOpen Targets
0.58Moderate
chronic progressive multiple sclerosisOpen Targets
0.46Moderate
secondary progressive multiple sclerosisOpen Targets
0.44Moderate
primary progressive multiple sclerosisOpen Targets
0.40Moderate
kidney transplantOpen Targets
0.39Weak
Crohn's diseaseOpen Targets
0.39Weak
systemic lupus erythematosusOpen Targets
0.38Weak
hyperaldosteronismOpen Targets
0.30Weak
hepatocellular carcinomaOpen Targets
0.29Weak
non-small cell lung carcinomaOpen Targets
0.27Weak
response to stimulusOpen Targets
0.27Weak
adult acute myeloid leukemiaOpen Targets
0.26Weak
chronic inflammatory demyelinating polyradiculoneuropathyOpen Targets
0.26Weak
preeclampsiaOpen Targets
0.24Weak
breast benign neoplasmOpen Targets
0.23Weak
hypothyroidismOpen Targets
0.20Weak
smoking initiationOpen Targets
0.18Weak
obesityOpen Targets
0.15Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets14
AMISELIMODPhase II
Sphingosine 1-phosphate receptor modulator
ulcerative colitis
AMISELIMOD HYDROCHLORIDEPhase II
Sphingosine 1-phosphate receptor modulator
Crohn's disease
CENERIMODPhase III
Sphingosine 1-phosphate receptor Edg-1 modulator
systemic lupus erythematosus
ETRASIMODApproved
Sphingosine 1-phosphate receptor Edg-1 agonist
ulcerative colitis
ETRASIMOD ARGININEApproved
Sphingosine 1-phosphate receptor Edg-8 modulator
ulcerative colitis
FINGOLIMODApproved
Sphingosine 1-phosphate receptor agonist
primary progressive multiple sclerosis
FINGOLIMOD HYDROCHLORIDEApproved
Sphingosine 1-phosphate receptor agonist
multiple sclerosis
FINGOLIMOD LAURYL SULFATEApproved
Sphingosine 1-phosphate receptor binding agent
multiple sclerosis
MOCRAVIMODPhase III
Sphingosine 1-phosphate receptor Edg-1 agonist
adult acute myeloid leukemia
OZANIMODApproved
Sphingosine 1-phosphate receptor Edg-1 modulator
multiple sclerosis
OZANIMOD HYDROCHLORIDEApproved
Sphingosine 1-phosphate receptor Edg-1 modulator
multiple sclerosis
PONESIMODApproved
Sphingosine 1-phosphate receptor Edg-1 agonist
multiple sclerosis
SIPONIMODApproved
Sphingosine 1-phosphate receptor Edg-1 agonist
multiple sclerosis
SIPONIMOD FUMARIC ACIDApproved
Sphingosine 1-phosphate receptor Edg-1 agonist
Related Genes
CD69Protein interaction100%S1PR4Protein interaction95%GNB1Protein interaction92%GNAI2Protein interaction91%GNAI1Protein interaction91%GNAI3Protein interaction91%
Tissue Expression6 tissues
Heart
100%
Lung
96%
Brain
42%
Bone Marrow
27%
Liver
13%
Ovary
7%
Gene Interaction Network
Click a node to explore
S1PR1CD69S1PR4GNB1GNAI2GNAI1GNAI3
PROTEIN STRUCTURE
Preparing viewer…
PDB7TD4 · 2.60 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.32Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.10 [0.04–0.32]
RankingsWhere S1PR1 stands among ~20K protein-coding genes
  • #1,694of 20,598
    Most Researched235 · top 10%
  • #155of 1,025
    FDA-Approved Drug Targets10 · top quartile
  • #1,307of 17,882
    Most Constrained (LOEUF)0.32 · top 10%
Genes detectedS1PR1
Sources retrieved26 papers
Response time—
📄 Sources
26▼
1
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.
PMID: 39551792
J Exp Clin Cancer Res · 2024
1.00
2
Bioinformatics identification and validation of biomarkers and infiltrating immune cells in endometriosis.
PMID: 36524127
Front Immunol · 2022
0.90
3
Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology.
PMID: 32278039
Pharmacol Res · 2020
0.80
4
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
PMID: 33983615
Drugs · 2021
0.70
5
Sphingosine-1-phosphate derived from PRP-Exos promotes angiogenesis in diabetic wound healing via the S1PR1/AKT/FN1 signalling pathway.
PMID: 37251708
Burns Trauma · 2023
0.64